Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Clinerion AG. (3/19/18). "Press Release: Ian Rentsch Is Clinerion’s New CEO". Basel.

Organisations Organisation Clinerion AG
  Group Clinerion (Group)
  Organisation 2 Quintiles (Group)
  Today QuintilesIMS (Group)
  Group Iqvia (Group)
Products Product clinical research software
  Product 2 clinical research services
Person Person Rentsch, Ian (Clinerion 201804– CEO before Iqvia/Quintiles since 2012)

Clinerion’s Board of Directors announces the appointment of Ian Rentsch as new CEO of the company, effective April 1, 2018.

Clinerion, the leading supplier of patient data analytics services for clinical trial patient search and identification, and data generation for real-world evidence and market access with access to currently more than 180 million patients’ data around the world, has appointed Ian Rentsch as its new CEO.

Rentsch brings more than 21 years of international experience in multinational pharmaceutical companies as well as in small/niche and global CROs. He joined the former Quintiles – now IQVIA – in 2012, as Head of Latin America Sales, and relocated to Europe to lead the Emerging Biopharma Segment in EMEA as Regional Head. Most recently, he took on the role of Global Demand and Business Operations Head of an E2E Strategic Alliance.

Rentsch has a German-Argentinian background and is a lawyer (UBA) and Industriekaufmann (IHK) by training.

Taking on leadership of Clinerion, Ian aims to solve the main industry challenge by bridging the divide between patients, sites, and drug developers. “Patients often lack access to clinical trials. Investigational sites struggle to identify the right patients and meet enrollment projections. Biopharma/CROs need to speed up the time-to-market, overcome study delays and leverage real-world and real-time data from real patients. Clinerion brings all three together on its technology platform,” says Rentsch.

“It’s an opportune time in the life sciences industry for a company like Clinerion. The company’s focus on electronic health data and innovative technologies allows it to reimagine how clinical research is conducted and how sites and patient communities around the world become engaged. A new era is coming and a datadriven approach illuminates the way to a promising future for human health.” says Rentsch.

“Clinerion is now well established. We have a truly global footprint and we are poised to expand further around the world. We can support international studies wherever they may have recruitment needs. Ian Rentsch is the right person to take the company to the next level of success,” says Ulf Claesson, current CEO and Board Director of Clinerion.

Ian Rentsch takes over from Ulf Claesson. “Ulf will continue to add his tremendous know-how to the company strategy at the board level. He has built Clinerion into a vibrant, dynamic company with a worldclass team capable of moving mountains! Clinerion is in position to radically speed up clinical research to the benefit of patients around the world. Ulf has done an invaluable job in building the technological and data fundaments of Clinerion and we are fortunate to continue to have him on the Board. I’m also very happy to have in Ian a new CEO who will build the bridge between our groundbreaking offering and customers in the increasingly digitalizing healthcare environment,“ says Pierre Jaccoud, Co-Founder and Chairman of Clinerion’s Board of Directors.

Ian Rentsch’s effective start date as CEO of Clinerion will be April 1, 2018. He will attend a few upcoming events with Clinerion, including DIA Europe, the Clinical Trial Innovation Summit in Boston and he will be speaking at the MAGI EAST Clinical Research Conference.

About Clinerion

Clinerion enables early patient access to innovative treatments through solutions for clinical trial patient recruitment, real-world evidence, and market access. Clinerion's PRS accelerates clinical research by radically improving the efficiency and effectiveness of trial recruitment. Clinerion’s key patient data services include data-assisted protocol optimization, site feasibility evaluation and patient identification. Clinerion’s solutions allow member hospitals to participate in leading-edge, industry-sponsored trials and save time in patient recruitment. They enable pharmaceutical companies to gain time and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage realtime data from electronic health records which remain under the full control of participating hospitals. Clinerion's solutions comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website:
Clinerion’s PRS:

For more information, please contact:

Le Vin Chin
Head of Marketing and Communications
Clinerion Ltd
Margarethenstrasse 47, CH-4053 Basel, Switzerland
Tel.: +41 61 865 60 54

Record changed: 2018-07-11


Picture EBD Group Global Partnering Four Events One Price 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top